ARTL Artelo Biosciences, Inc. Stock Quote

ARTL [NASD]

Index	-	P/E	-	EPS (ttm)	-0.57	Insider Own	5.07%	Shs Outstand	23.11M	Perf Week	-11.76%
Market Cap	16.00M	Forward P/E	-	EPS next Y	-0.35	Insider Trans	0.00%	Shs Float	21.55M	Perf Month	-11.96%
Income	-6.60M	PEG	-	EPS next Q	-0.08	Inst Own	16.30%	Short Float	5.90%	Perf Quarter	-30.84%
Sales	-	P/S	-	EPS this Y	-25.60%	Inst Trans	-15.94%	Short Ratio	0.16	Perf Half Y	-48.36%
Book/sh	0.52	P/B	1.21	EPS next Y	9.30%	ROA	-66.30%	Target Price	4.67	Perf Year	2.56%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-69.80%	52W Range	0.55 - 3.67	Perf YTD	-13.70%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-82.72%	Beta	3.10
Dividend %	-	Quick Ratio	24.30	Sales past 5Y	-	Gross Margin	-	52W Low	15.27%	ATR	0.10
Employees	4	Current Ratio	24.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	32.71	Volatility	11.30% 13.71%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	64.50%	Profit Margin	-	Rel Volume	0.18	Prev Close	0.63
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 29 BMO	Payout	-	Avg Volume	7.84M	Price	0.63
Recom	1.50	SMA20	-26.94%	SMA50	-21.54%	SMA200	-45.88%	Volume	871,606	Change	0.63%

Feb-12-21

Initiated

Ladenburg Thalmann

Buy

Nov-29-21 08:30AM	Artelo Biosciences Reports Fiscal 2021 Year-End Financial Results and Provides Business Update GlobeNewswire -6.95%
Nov-11-21 08:30AM	Artelo Biosciences to Present at the Q4 Investor Summit on November 17th Newsfile -7.45%
Nov-02-21 07:33AM	We Think Artelo Biosciences (NASDAQ:ARTL) Needs To Drive Business Growth Carefully Simply Wall St. +14.93%
Sep-08-21 08:30AM	Artelo Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire
Aug-11-21 04:18PM	Artelo Biosciences to Present at the Q3 Virtual Investor Summit on August 18th Newsfile
Aug-04-21 08:30AM	Artelo Biosciences Announces Publication of Study Results Comparing the Pharmacological Effects of Plant-Derived Versus Synthetic Cannabidiol in Human Cell Lines GlobeNewswire
Jul-21-21 08:30AM	Ladenburg Thalmann to Host R&D Showcase Featuring Artelo Biosciences CAReS Study on July 28, 2021 GlobeNewswire
Jul-12-21 08:30AM	Artelo Biosciences Reports Third Quarter Fiscal 2021 Financial Results and Provides Business Update GlobeNewswire
Jul-07-21 08:30AM	Artelo Biosciences to Present at the 2021 Ladenburg Thalmann Healthcare Conference on July 14th GlobeNewswire -8.55%
Jun-22-21 08:00AM	Artelo Biosciences Announces Two Poster Presentations Featured at the 31st Annual ICRS Symposium GlobeNewswire
Jun-02-21 08:30AM	Artelo Biosciences to Present at the LD Micro Virtual Invitational XI on June 9th GlobeNewswire
May-06-21 07:00AM	Artelo Biosciences to Participate at the Benzinga Global Small Cap Conference on May 13, 2021 Newsfile
May-04-21 08:00AM	Kintara Therapeutics Appoints Tamara A. Seymour to Board of Directors PR Newswire -5.84%
Apr-20-21 02:02AM	We're Hopeful That Artelo Biosciences (NASDAQ:ARTL) Will Use Its Cash Wisely Simply Wall St. -9.52%
Apr-13-21 08:30AM	Artelo Biosciences Reports Second Quarter Fiscal 2021 Financial Results and Provides Business Update GlobeNewswire
Apr-12-21 08:30AM	Artelo Biosciences Doses First Patient in CAReS Study with ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss GlobeNewswire -9.21%
Mar-19-21 10:00AM	Artelo Biosciences Accepted into the Alderley Park Oncology Development Program for FABP5 Inhibitor Biomarker Development GlobeNewswire
Mar-11-21 07:10AM	Artelo Biosciences, Inc. to Present at the Q1 Virtual Investor Summit on March 23rd GlobeNewswire
Mar-09-21 08:30AM	Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors GlobeNewswire +22.37%
Mar-02-21 08:30AM	Artelo Biosciences to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th GlobeNewswire -6.10%
Feb-17-21 08:30AM	Artelo Biosciences Announces Positive Pre-Clinical Data Associated with Proprietary CBD Cocrystal GlobeNewswire +14.18%
Feb-16-21 08:30AM	Artelo Biosciences Announces Appointment of Andrew Yates, Ph.D. as Senior Vice President and Chief Scientific Officer GlobeNewswire
Feb-12-21 10:56AM	ARTL Stock Alert: The Big Reason Biopharma Artelo Biosciences Is Rocketing Today InvestorPlace +63.19%
Feb-08-21 08:30AM	Artelo Biosciences Receives $3.0 Million in Net Proceeds from Exercise of Warrants GlobeNewswire +8.47%
Feb-02-21 08:30AM	Artelo Biosciences Announces Research Collaboration with Trinity College Dublin to Investigate ART27.13 for the Treatment of Cancer Cachexia GlobeNewswire +20.19%
Jan-29-21 04:05PM	Artelo Biosciences to Present at the LSX World Congress Virtual Conference GlobeNewswire +6.39%
Jan-14-21 08:30AM	Artelo Biosciences Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Update GlobeNewswire
Jan-05-21 08:30AM	Artelo Biosciences to Present at the H.C. Wainwright BioConnect 2021 Conference GlobeNewswire
Dec-09-20 08:30AM	Artelo Biosciences Files Patent Application for New Formulation of ART27.13 GlobeNewswire +11.69%
Dec-08-20 08:30AM	Artelo Biosciences to Present at The 13th Annual LD Micro Main Event Conference on December 15th GlobeNewswire
Dec-02-20 08:30AM	Artelo Biosciences Announces Appointment of Senior Pharmaceutical Executive Gregory R. Reyes, M.D., Ph.D., to Board of Directors GlobeNewswire +15.69%
Nov-23-20 08:30AM	Artelo Biosciences and University of Western Ontario Awarded Research Grant by Mitacs GlobeNewswire
Nov-16-20 08:30AM	Artelo Biosciences Announces Clinical Trial Authorization to Commence Cancer Appetite Recovery Study for the Treatment of Cancer-Related Anorexia and Weight Loss GlobeNewswire
Nov-11-20 08:30AM	Artelo Biosciences to Present at the Virtual Fall Investor Summit on November 18th ACCESSWIRE
Nov-04-20 08:00AM	Artelo Biosciences Reports Fourth Quarter and Fiscal 2020 Year-End Financial Results and Provides Business Update GlobeNewswire
Nov-02-20 05:48AM	Did Artelo Biosciences, Inc. (NASDAQ:ARTL) Insiders Buy Up More Shares? Simply Wall St. +5.18%
Oct-21-20 08:30AM	Artelo Biosciences Files Patent on Use of Fatty Acid Binding Protein 5 Inhibitors for Treating Psychological Disorders GlobeNewswire
Oct-14-20 04:05PM	Artelo Biosciences, Inc. Announces Closing of $7.6 Million Underwritten Public Offering and Full Exercise of Underwriters Option GlobeNewswire
Oct-09-20 08:30AM	Artelo Biosciences, Inc. Announces Pricing of $6.6 Million Upsized Underwritten Public Offering GlobeNewswire -5.29%
Sep-29-20 08:00AM	Artelo Biosciences Receives Ethics Approval to Commence its Cancer Appetite Recovery Phase I/II Clinical Study (CAReS) of ART27.13 for the Treatment of Cancer-Related Anorexia GlobeNewswire +11.26%
Sep-11-20 09:00AM	Artelo Biosciences to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15th GlobeNewswire -5.32%
Sep-10-20 09:15AM	Artelo Biosciences to Participate in Two Keynote Panels at 3rd Annual International Cannabinoid Derived Pharmaceutical Summit GlobeNewswire -9.62%
Aug-31-20 06:12PM	LD Micro: 360 Companies - Set to Present this Week ACCESSWIRE
Aug-26-20 09:30AM	Artelo Biosciences to Present at The LD 500 Virtual Investor Conference on September 1st ACCESSWIRE +25.00%
Aug-05-20 11:04AM	LD Micro Announces Preliminary List of Presenters for the LD-500. ACCESSWIRE
Jul-14-20 09:25AM	Artelo Biosciences Reports Third Quarter Fiscal Year 2020 Financial Results and Provides Business Update GlobeNewswire -12.00%
Jun-29-20 08:30AM	Artelo Biosciences Expands Stony Brook Commercial License Agreement for FABP5 Platform for Development of Lead Cancer, Pain and Inflammation Compounds GlobeNewswire
Jun-03-20 09:30AM	Artelo Biosciences to Participate in BIO Digital and The Investor Summit Conferences GlobeNewswire -15.95%
09:00AM	47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th ACCESSWIRE
May-12-20 09:30AM	Artelo Biosciences Awarded Composition of Matter Patent for Novel CBD Cocrystal GlobeNewswire -9.63%
May-06-20 09:09AM	Independent Chairperson of the Board Connie Matsui Just Bought 278% More Shares In Artelo Biosciences, Inc. (NASDAQ:ARTL) Simply Wall St.
Apr-14-20 08:30AM	Artelo Biosciences Reports Second Quarter Fiscal Year 2020 Financial Results and Provides Business Update GlobeNewswire +31.43%
Mar-23-20 09:00AM	Artelo Biosciences to Present at the Spring Investor Summit on March 25th ACCESSWIRE +18.56%
Mar-02-20 09:07AM	Here's Why We're A Bit Worried About Artelo Biosciences's (NASDAQ:ARTL) Cash Burn Situation Simply Wall St. +24.77%
Feb-24-20 09:00AM	Artelo Biosciences to Present at Biocoms 10th Annual Global Life Sciences Partnering Conference GlobeNewswire
Feb-03-20 11:42AM	Artelo's stock soars after NCI grant to develop cancer treatment MarketWatch +35.47%
08:30AM	Artelo Biosciences Announces NCI Grant of $4.2 Million to Stony Brook University to Advance FABP5 Inhibitor Cancer Program GlobeNewswire
Jan-29-20 09:00AM	Artelo Biosciences to Present at the LSX World Congress in London GlobeNewswire
Jan-14-20 08:00AM	Artelo Biosciences Reports First Quarter Fiscal Year 2020 Financial Results and Provides Business Update GlobeNewswire
Dec-09-19 08:30AM	Artelo Biosciences Announces Appointment of Seasoned Finance and Industry Executive John W. Beck to Board of Directors GlobeNewswire
Nov-25-19 08:00AM	Artelo Biosciences Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update GlobeNewswire -8.13%
Nov-18-19 08:30AM	Artelo Biosciences Announces Publication of Positive Non-Clinical Fatty Acid Binding Protein 5 Inhibitor Data in Peer-Reviewed Journal GlobeNewswire
Nov-14-19 09:00AM	Artelo Biosciences to Present at the Annual Investival Showcase in London GlobeNewswire
Oct-29-19 08:30AM	Artelo Biosciences Announces Selection of Aptus Clinical Ltd. as Clinical Research Organization for Phase 1b/2a Study of ART27.13 GlobeNewswire -5.65%
Oct-22-19 09:00AM	Artelo Biosciences to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference GlobeNewswire
Sep-18-19 08:00AM	Artelo Biosciences Cannabidiol (CBD) Studies Referenced in September Issue of Nature Medicine GlobeNewswire
Sep-11-19 09:00AM	Artelo Biosciences to Present at the Fall Investor Summit in New York City on September 17th ACCESSWIRE +7.29%
Sep-04-19 01:34PM	What Percentage Of Artelo Biosciences, Inc. (NASDAQ:ARTL) Shares Do Insiders Own? Simply Wall St.
Jul-15-19 04:01PM	Artelo Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Jul-10-19 07:23AM	Cannabis stocks dragged down by CannTrusts losses after cannabis seizure MarketWatch -8.10%
Jun-25-19 01:00PM	Artelo Biosciences Announces Closing of $8.0 Million Public Offering and Partial Exercise and Closing of Over-Allotment Option GlobeNewswire -6.69%
May-08-19 04:05PM	Artelo Biosciences Retains Crescendo Communications, LLC for Investor Relations Services ACCESSWIRE
Jan-03-19 07:00AM	Artelo Biosciences Retains Maxim Group LLC to Provide Financial Advisory and Investment Banking Services ACCESSWIRE
Oct-09-18 08:00AM	New Preclinical Cell-Line Data of Artelo Biosciences' ART27.13 Demonstrate Anti-Proliferative Activity in Tumor Models ACCESSWIRE
Jul-03-18 08:00AM	Artelo Biosciences Announces Five Year Commitment To Sponsor The Young Investigator Award At The International Cannabinoid Research Society Annual Symposium PR Newswire

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences has research collaboration with Trinity College Dublin to Investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was founded in 2011 and is headquartered in La Jolla, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gorgas Gregory D.	Pres, CEO, CFO, Treas & Secr	Apr 16	Buy	1.15	8,500	9,809	270,676	Apr 20 04:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience